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ScreeningA B S T R A C T
Aims: To test the performance of the cardiac vagal tone (CVT) derived from a 5-minute ECG
recording compared with the standardized cardiovascular autonomic reflex tests (CARTs).
Methods: Cross-sectional study included 56 well-phenotyped adults with type 1 diabetes
(19–71 years, 2–54 years disease-duration). Autonomic testing included: standardized
CARTs obtained with the VAGUSTM, CVT, and indices of heart rate variability (HRV) obtained
at 24- and 120-hour, and electrochemical skin conductance assessed with SUDOSCAN.
ROC AUC and cut-off values were calculated for CVT to recognize CAN based on  2 (estab-
lished CAN, n = 7) or 1 (borderline CAN, n = 9) abnormal CARTs and compared to HRV indices
and electrochemical skin conductance.
Results: Established CAN: The cut-off CVT value of 3.2LVS showed 67% sensitivity and 87%
specificity (p = 0.01). Indices of HRV at either 24-hour (AUC > 0.90) and 120-hour
(AUC > 0.88) performed better than CVT. Borderline CAN: The cut-off CVT value of 5.2LVS
indicated 88% sensitivity and 63% specificity (p = 0.07). CVT performed better than HRV
indices (AUC < 0.72). Electrochemical skin conductance (AUC:0.63–0.72) had lower sensitiv-
ity and specificity compared with CVT.
Conclusions: Implementation of CVTwith a clinically applicable cut-off value may be con-
sidered a quicker and accessible screening tool which could ultimately decrease the num-
ber of unrecognized CAN and initiate earlier prevention initiatives.
 2020 The Author(s). Published by Elsevier B.V. This is an open access articleunder theCCBY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The development of cardiovascular autonomic neuropathy
(CAN) is a frequent and severe complication of type 1 diabetes
[1,2]. The presence hereof independently predicts mortality
and is strongly associated with cardiovascular diseases
involving silent myocardial ischemia, coronary heart disease,
arrhythmia, and other major cardiovascular events, [3,4] as
well as hypoglycemic unawareness [5]. Pathologically, CAN
encompasses disruption of coordinated heart control due to
a diminution of sympathetic and parasympathetic neuronal
function combined with secondary metabolic, oxidative, and
inflammatory processes characteristic of long-term hyper-
glycemia [2,6]. However, asymptomatic CAN is often unrecog-
nized and current routine testing is not recommended until
five years after type 1 diabetes diagnosis [2,7].
Cardiovascular autonomic reflex tests (CARTs) remain the
gold standard for CAN diagnosis, assessing the heart rate
responses to deep breathing, postural change, the Valsalva
maneuver, and orthostatic blood pressure alterations [1,8,9];
however, these are not readily accessible in the routine clini-
cal practice. Current evidence shows that CAN, diagnosed
based on CARTs may be present in up to 7% of people with
type 1 diabetes at the time of diagnosis, and the prevalence
increases hereafter with approximately 2% annually [10].
Thus, there is an unmet clinical need for early recognition
of CAN [6]. Indices of heart rate variability (HRV) in time-
and frequency-domains derived from 24-hour or more
recently shorter electrocardiograms have been used to recog-
nize early asymptomatic CAN[1,6,11]; however, differences in
the techniques, length of recordings, and the software used
raise challenges in correctly establishing cut-off values to
compare different populations. More recently, the handheld
VagusTM was developed to perform three standardized CARTs
based on heart rate during a 30-minute bedside procedure.
Based on age-dependent cut-off values this procedure gener-
ates CAN scores used to differentiate between borderline and
established CAN as previously reported [12,13]. In addition,
assessment of sudomotor function through electrochemical
skin conductance (ESC) during a 3-minute test with the
SUDOSCAN has been proposed as a rapid alternative; how-
ever, large variability in data generated by different groups,
as well a recent meta-analysis, question the SUDOSCAN
ESC sensitivity as a reliable test for CAN [14–16]. All the
above-mentioned methods are also either unavailable,
resource-demanding, or expensive to perform in standard
clinical practice [12,13]. Therefore, the implementation of
simpler and readily available tests to document the presence
of asymptomatic CAN is needed [17].
Cardiac vagal tone (CVT) is derived from a 5-minute rest-
ing electrocardiogram and is decreased in adults with type 1
diabetes and polyneuropathy [18]. In addition, it shows a good
correlation to 24-hour HRV indices and thus, has been sug-
gested as a novel marker of parasympathetic activity [18]. Fur-
thermore, CVT does not require active participation or
complicated instructions, making the case for ready applica-
bility in standard clinical practice [18,19].
We hypothesized that a 5-minute CVT recording could
serve as a clinically applicable screening method for recogni-tion of established and borderline CAN. The primary objective
was to test the sensitivity and specificity of CVT for recogniz-
ing CAN compared with the standardized CARTs. Secondary
objectives included comparing CVT with indices of HRV and
explorative sudomotor function.
2. Subjects
This cross-sectional study included 56 adults with type 1 dia-
betes, of European descent, receiving stable antihyper-
glycemic medication (consisting of either long-/fast-acting
insulin injections or insulin pump use with dosing adjusted
according to standard regimens for at least 3 months). Exclu-
sion criteria included established cardiovascular disease, cur-
rent or previous alcohol consumption above the limits
recommended by the Danish health authorities and/or recre-
ational drugs use, current or prior chemotherapy, or any com-
peting diagnoses reflecting neurological and/or psychiatric
diseases. Participants were recruited from November 2017 to
November 2018 from the outpatient clinic at the Department
of Endocrinology, Aalborg University Hospital, Denmark, and
from advertisement at the local diabetes association. The
study was conducted in accordance with the Declaration of
Helsinki and GCP guidelines, was approved by The North Den-
mark Region Committee on Health Research Ethics (N-
20170045), and all research participants signed written
consent.
3. Materials and methods
3.1. Assessment of demographic and cardio-metabolic
factors
Demographic and clinical data including age, sex, diabetes
duration, smoking status, presence of retinopathy, and use
of insulin and other relevant pharmaceuticals were obtained
from participants during the study visit and confirmed by
the participants’ medical record. Height was measured using
a stadiometer (Seca GmbH & Co. KG., Hamburg, Deutschland)
and weight was assessed with a standardized calibrated scale
(BWB-800AS, Tanita, Arlington Heights, Illinois, USA). Heart
rate, resting systolic and diastolic blood pressure were
obtained after a 5-minute rest in a seated position using a
blood pressure monitor (Intellisense, Omron Healthcare,
Inc., Bannockburn, Illinois, USA). Fasting blood samples were
assessed for glucose, hemoglobin A1c, estimated glomeruli
filtration rate, and lipid panel (total cholesterol, triglycerides,
high-density lipoprotein cholesterol, and low-density lipopro-
tein cholesterol), while urine samples were obtained to esti-
mate albumin-creatinine ratio. Both blood and urine
samples were analyzed at the Department of Clinical Bio-
chemistry, Aalborg University Hospital according to standard
laboratory procedures.
3.2. Assessment of cardiac vagal tone
CVT is a validated cardiometrically derived index of parasym-
pathetic efferent tone and thus, measures the brainstem
efferent modulation of the heart [20]. Based on a reflex, the
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of baroreceptor stretching, parasympathetic vagal activation,
and sinoatrial depolarization [7]. During rest, the relationship
between the cardiac cycle, measured as R-R intervals, and the
vagal efferent modulation resembles linearity and can be
quantified on a linear vagal scale (LVS). On the LVS, zero rep-
resents atropinization, and measures above zero represent an
efferent vagal tone, with higher measures indicating healthy
parasympathetic function [19,21]. Participants were asked to
refrain from coffee two hours prior to testing. Following a 5-
minute relaxation period, a simple 3-lead electrocardiography
(eMotion Faros 180 device (Bittium, Oulu, Finland)) was under-
taken with electrodes (Ambu Blue Sensor P, Ballerup, Den-
mark) placed on the right and left subclavicular areas and at
the cardiac apex. CVT was computed by the ProBioMetrics
online app version 1.0 (ProBioMetrics, Kent, UK). Recording
artifacts were defined as a change in two succeeding QRS
complexes exceeding 15 beats per minute (e.g. coughing or
movement), and consequently, files were inspected and
cleaned by removing five heartbeats before and after in order
to derive the true CVT. The file was discarded if the number of
edited heartbeats exceeded 20%.
3.3. Assessment of cardiovascular autonomic neuropathy
To minimize the influence of circadian rhythm, all partici-
pants underwent cardiovascular autonomic reflex testing in
the morning (between 8:00 and 10:00 a.m.) in a constantly
lit, quiet laboratory. We used the VagusTM device (Medicus
Engineering ApS, Aarhus, Denmark), which has previously
been validated with high diagnostic agreement against sta-
tionary equipment [13,22]. The testing includes electrocardio-
graphic recordings at rest and during cardiovascular
autonomic reflex tests comprised of expiration: inspiration
ratio (deep breathing), Valsalva ratio, and 30:15 supine to
standing ratio (postural change). The test was performed by
a trained examiner (ALW), preceded by 10 min of rest. The
CAN score was calculated based on these three examinations;
however, if one cardiovascular autonomic reflex test was not
completed, the CAN score was estimated from the remaining
two procedures.
Established CAN was defined as two or more abnormal
tests, borderline CAN by one abnormal test, and no CAN when
the obtained tests were within the normal range of the speci-
fic age-dependent cut-off values [9].
3.4. Assessment of heart rate variability
Time- and frequency-domain indices of HRV were derived
from 24-hour or 120-hour electrocardiogram using the
ePatch (BioTelemetry Technology, Hørsholm, Denmark).
The ePatch system consists of the directly connected
single-use, biocompatible, 3-lead electrode, and a recharge-
able sensor. HRV indices were derived from R-R intervals
using the CardiScopeTM analysis software which prepared
and filtered the recordings automatically (HASIBA Medical
GmbH, Graz, Austria). Analyses were carried out at the
Department of Cardiology at Aalborg University Hospital.
Based on the recommendation from the Task Force of the
European Society of Cardiology and the North American Soci-ety of Pacing and Electrophysiology, [23] heart rate (HR) and
the following four time-domain HRV indices were used: 1)
SDNN: standard deviation of normal-to-normal intervals; 2)
SDANN: standard deviation of the average normal-to-
normal intervals for each 5-minute segment of the recording;
3) SDNNI: Mean of the standard deviation of all the normal-
to-normal intervals for each 5-minute segment of the record-
ing; 4) RMSSD: root mean square of successive RR interval dif-
ferences. In addition, the following four frequency-domain
HRV indices were used: 1) VLF: absolute power of the very-
low-frequency band (0.0033–0.04 Hz); 2) LF: absolute power
of the low-frequency band (0.04–0.15 Hz); 3) HF: absolute
power of the high-frequency band (0.15–0.4 Hz); and 4) LF:
HF: Ratio of LF-to-HF power. The content of VLF and LF are tra-
ditionally thought to represent the sympathetic activity, in
contrast to HF and RMSSD which are considered to represent
parasympathetic control. [24] LF:HF ratio is considered to
reflect the sympato-vagal balance.
3.5. Assessment of sudomotor function
We used SUDOSCAN (Impeto Medical, Paris, France) to
assess the sudomotor function. This device measures the
electrochemical reaction between the chloride ions in the
sweat glands and the steel electrodes[15] and provides an
ESC readout for all four extremities. Participants placed their
hands and feet on the stainless-steel electrodes emitting a
low current for 3 min. The average value for hands and feet
was used in this study.3.6. Outcome measures:
The primary outcome was to test the sensitivity and speci-
ficity of the 5-minute CVT compared with established CARTS.
The secondary outcomes were to test the performance of the
5-minute CVT compared with indices of HRV and ESC.3.7. Statistical analysis
CAN was stratified into three categories: no CAN, borderline
CAN, and established CAN, and descriptive statistics for demo-
graphics and cardiometabolic factors for each stratification
were reported depending on normality as mean and standard
deviations or median and range for the continuous variables
and number (percentage) for the categorical variables. Differ-
ences between CAN stratifications for demographics and car-
diometabolic factors were performed depending on normality
as a one-way ANOVA or Kruskal Wallis test, with Tukey’s test
for post hoc analysis of continuous variables and Fisher’s
exact test for categorical data.
Logistic regression receiver operating characteristic (ROC)
curves were used to illustrate the sensitivity and specificity
of CVT, HRV, and ECS for recognizing established CAN or border-
line CAN. Further, the ROC provided areas under the curve
(AUC) which calculates the performance of CVT, HRV, and
ECS. Finally, based on Youden´s index, the optimal cut-off
value for CVT to recognize established CAN and borderline
CAN was suggested. All statistical analyses were performed
using STATA software (StataCorp LLC, version 15.1).
4 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 0 ( 2 0 2 0 ) 1 0 8 5 1 74. Results
4.1. Diagnosis of cardiovascular autonomic neuropathy
The CAN score was unobtainable in six participants, as they
had difficulties completing the active participation required
for abnormal cardiovascular autonomic reflex tests, leaving
50 participants with valid tests. Participants were 19 to
71 years old (average 42 years), had type 1 diabetes between
2 and 54 years (average 22 years), with an average hemoglobin
A1C of 62 mmol/mol, and a near equal distribution of gender
(54% females). The presence of CAN was diagnosed in 32%
(14% established CAN and 18% borderline CAN). Table 1 presents
the clinical and cardiometabolic factors of the participants
stratified by the presence of CAN, while the autonomic char-
acteristics of the participants stratified by the presence of
CAN are presented in the supplementary materials. There
were no differences in age or disease duration between par-
ticipants with no CAN, borderline CAN, and established CAN
(p > 0.05). In participants with established CAN, proliferative
retinopathy was more prevalent in comparison to no CAN
(43% vs. 3%, p = 0.01).Table 1 – Demography, Diabetes risk factors and Cadiac risk fac
cardiovascular autonomic neruopathy (CAN).
Variable No
CAN
(n = 34
Demography Age (years) 35 (19–
Male gender 17 (50%
Body mass index 26 ± 4
Diabetes Disease duration (years) 18 (2–5
risk factors HbA1C (mmol/mol) 60 ± 1
Glucose (mg/dl) 188 ±
Insulin dose (IU) 42.5 ±
Retinopathy
Simplex 4 (12%
Proliferative 1 (3%)
Maculopathy 4 (12%
eGFR (ml/min) 90 (75–
Albumin/creatinine ratio 9 (3–10
Cardiac Cardiac vagal tone 6.6 (3.7
risk factors Systolic blood pressure (mmHg) 133 ±
Diastolic blood pressure (mmHg) 74 ± 8
Heart rate (beats/min) 69 ± 9
Smoking
Current smoker 5 (15%
Previous smoker 4 (12%
Social smoker 5 (15%
Cholesterol (mmol/l) 4.4 ± 1
Triglyceride (mmol/l) 0.8 (0.4
HDL cholesterol (mmol/l) 1.6 (0.8
LDL cholesterol (mmol/l) 2.3 (0.7
Use of antihypertensive 8 (24%
Use of statins 8 (24%
Use of aspirin 2 (6%)
Descriptive data stratified on no, borderline, and established cardiovascu
deviations, median (range), and number (%). Stratifications of no, border
Kruskal Wallis test, with Turkeys test as post hoc, or a v2-test.
 A significant difference was found between no CAN and established CAN
Abbreviations: eGFR – estimated glomerular filtration rate; HDL – high-den4.2. Cardiac vagal tone
All participants with a valid CART test completed the CVT
recording, however, 6 files were discarded due to poor data
quality leaving 44 participants with the results from both
tests. The performance of CVT for recognizing established
CAN and borderline CAN is shown in Table 2. A CVT cut-off
value of 3.2 LVS showed 67% sensitivity and 87% specificity
for recognition of established CAN at an AUC of 0.80
(p = 0.01). Similarly, a CVT cut-off value of 5.2 LVS had 88%
sensitivity and 63% specificity for recognition of borderline
CAN, at an AUC of 0.72 (p = 0.07).
4.3. Heart rate variability indices
24-hour HRV analyses: Of participants with valid CART and
CVT tests, 7 of the 24-hour HRV recordings were discarded
due to poor data quality, leaving 37 participants for analysis.
The performance of CVT in comparison to 24-hour HRV
indices for recognition of established and borderline CAN is
shown in Table 3 and depicted in as a figure in the Supple-
mentary material. For established CAN, the ROC AUC for singletors for participants with no-, bordeline-, and established
)
Borderline
CAN
(n = 9)
Established
CAN
(n = 7)
p-value
71) 49 (27–65) 45 (24–67) 0.35
) 5 (56%) 1 (14%) 0.18
.1 25 (22–35) 25 ± 2.9 0.90
4) 23 (3–48) 29 (9–44) 0.56
1 63 ± 7 74 ± 32 0.11
80 176 ± 49 176 ± 65 0.86
15.9 40.3 ± 19.4 44.8 ± 28 0.89
) 2 (22%) 1 (14%) 0.72
0 (0%) 3 (43%) <0.01 
) 0 (0%) 1 (14%) 0.53
90) 90 (63–90) 90 (33–90) 0.87
6) 11 (4–110) 33 (3–280) 0.20
–8.4) 3.8 (2.7–4.8) 2.6 (1.3–6.8) 0.02 
15 136 ± 13 132 ± 19 0.82
73 ± 9 74 ± 10 0.99
70 ± 9 75 ± 7 0.19
) 2 (22%) 0 (0%) 0.33
) 3 (33%) 3 (43%) 0.15
) 1 (11%) 0 (0%) 0.59
.0 4.5 ± 0.7 4.3 ± 0.5 0.94
–2) 0.9 ± 0.4 1.0 ± 0.4 0.79
–3.2) 1.7 ± 0.5 1.8 ± 0.2 0.21
–5.3) 2.3 ± 0.5 2.0 ± 0.5 0.48
) 3 (33%) 4 (57%) 0.20
) 4 (44%) 4 (57%) 0.15
2 (22%) 1 (14%) 0.32
lar autonomic neuropathy (CAN). Data presented as mean ± standard
line, and established CAN was compared using a one-way ANOVA or
sity lipoprotein; LDL – low-density lipoprotein.
Table 2 – Receiver operator curve for cardiac vagal tone (CVT) for determining borderline cardiovascular autonomic
neuropathy (CAN) and established CAN.
Borderline Established
Area under the curve 0.72 (0.51;0.93) 0.80 (0.58;1.00)
Sensitivity 0.88 (0.53;0.98) 0.67 (0.30;0.90)
Specificity 0.63 (0.46;0.78) 0.87 (0.70;0.95)
Positive predictive value 0.39 0.50
Negative predictive value 0.95 0.93
Cut-off value 5.24 3.18
P-value 0.07 0.01
Data is shown with 95% confidence intervals
The x-axis shows 1-specificity while the y-axis shows the sensitivity of the receiver operator characteristics curve as a black line with dots. The
dashed lines show the intersection of the sensitivity and specificity at the optimal cut point.
Table 3 – Area under the receiver operator curve for 24-hour
and 5 day heart rate variability measures to recognize
established or borderline CAN.
Established CAN Borderline CAN
24-hours 5-day 24-hours 5-day
HR (bpm) 0.90 0.93 0.42 0.58
SDNN (ms) 0.97 0.99 0.63 0.65
SDANN (ms) 0.92 0.98 0.57 0.66
SDNNi (ms) 0.94 0.96 0.64 0.64
RMSSD (ms) 0.94 0.92 0.74 0.76
VLF (ms2) 0.94 0.95 0.65 0.63
LF (ms2) 0.96 0.95 0.66 0.68
HF (ms2) 0.93 0.93 0.78 0.80
LF:HF 0.67 0.69 0.62 0.63
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 7 0 ( 2 0 2 0 ) 1 0 8 5 1 7 5HRV indices were larger (0.9–0.99) than CVT ROCAUC, demon-
strating the superior performance of HRV. However, the LF:HF
ratio ROC AUC was smaller (0.64) than CVT ROC AUC, which
indicates the superior performance of CVT for this measure.
In borderline CAN, the ROC AUC for all HRV indices were smal-
ler (0.41–0.7) than CVT ROC AUC, indicating the superior per-
formance of CVT to recognize this entity.
120-hour HRV analyses: Of participants with valid CART
and CVT tests, 12 of the 120-hour HRV recordings were dis-
carded due to poor data quality, leaving 32 participants for
analysis. The duration of the recordings was on average
118 ± 9 h. The performance of CVT in comparison to 120-
hour HRV indices for recognition of established and borderline
CAN is shown in Table 3 and depicted in as a figure in the Sup-
plementary material. In established CAN, the ROC AUC for sin-
gle HRV indices were larger (0.88–0.99) than CVT ROC AUC,
demonstrating the superior performance of HRV. However,
the LF:HF ratio ROC AUC was smaller (0.6) than CVT ROC
AUC, indicating the superior performance of CVT for this
measure. In borderline CAN, the ROC AUC for all HRV indices
(0.6–0.72) were smaller than CVT ROC AUC, indicating the
superior performance of CVT to recognize this entity.4.4. Sudomotor function
Fig. 1A-B shows ROC generated to plot the performance of
CVT compared to ECS of hands and feet for recognition of bor-
derline CAN and established CAN. In established CAN, the ROC
AUC for ESC of the hands (0.70) and feet (0.72) were smaller
than CVT ROC AUC. In borderline CAN, the ROC AUC for ESCof the hands (0.63) and feet (0.67) were smaller than CVT
ROC AUC.
5. Discussion
In this study, we demonstrate that the CVT, a simple test
derived from a 5-minute electrocardiogram recording, has
high sensitivity to recognize borderline CAN and a high speci-
ficity to recognize established CAN as diagnosed by standard-
ized CARTs. Thus, implementing the CVTwith the described
cut-off values is clinically applicable and suitable as a quick
screening tool, which could ultimately decrease the number
of unrecognized CAN and initiate earlier prevention initia-
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borderline cardiovascular autonomic neuropathy (CAN) and B) established CAN. The x-axis shows 1-specificity while the y-
axis shows sensitivity.
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1 diabetes, when assessed with cardiovascular autonomic
reflex testing, was 32%.
The present study revealed that the average CVT values
were decreased in participants with the presence of CAN in
comparison to no CAN. However, CVT in the group with estab-
lished CAN and borderline CAN were comparable with previous
findings in adults with type 1 diabetes, distal symmetrical
polyneuropathy, and concomitant orthostatic hypotension
[18,25]. Additionally, CVT values in the three CAN strata were
lower than CVT values reported in healthy subjects, [18,21]
indicating lower parasympathetic tone. However, it is worth
noting that in comparison to normative data obtained from
200 healthy humans (95% CI: 1.9–17.8 LVS), [21] we found that
only three out of 50 participants had CVT values below the
95th percentile, which may challenge the existing lower limit
of the confidence interval of normal cardiac vagal tone.
One-third of the participants in our cohort had a classifica-
tion of CAN. There were no differences in age and disease
duration between the three CAN strata, which may indicate
that the current standard of testing for CAN every year after
five years of a diagnosis of type 1 diabetes seems sensible.
Furthermore, as proliferative retinopathy was exclusively
reported in the group with established CAN, this relatively
common eye diagnosis should raise clinical awareness of
the need to test the autonomic nervous system in order to
recognize asymptomatic CAN.
Cardiovascular autonomic reflex testing is the gold stan-
dard for autonomic testing recommended by the Toronto con-
sensus [8]. However, the comprehensive and time-consuming
test paradigm of the cardiovascular reflex tests are not feasi-
ble in a clinical setting, where time is essential. Therefore, the
use of VagusTM is an acceptable clinical solution, but it needs
thorough instruction and active patient participation. In con-
trast, the less technical demanding CVT provides a quick
measure computed from a 5-minute electrocardiographic
recording. This was underscored by an excellent specificity
(87%) of CVT for recognizing established CAN and with the
introduction of a cut-off value of 3.2 LVS. The method pro-
vides an easily performed and readily applicable test, which
could not only aid healthcare professionals in recognizing
CAN in clinical settings but also provide a much-needed end-
point in clinical trials testing novel treatment approaches for
CAN. Thus, earlier recognition of CAN is pivotal as optimal
glycemic control may halt the progression of the entity.
In advanced autonomic testing, HRV should be considered
an addition to cardiovascular reflex testing, allowing supple-
mental prognostic information. However, cardiovascular
autonomic reflex testing and HRV are notorious for disagree-
ment when applied as diagnostic tools. Therefore, in estab-
lished CAN, we tested the performance of CVT against 24-
hour and 120-hour HRV indices. Our results indicate that all
single HRV indices performed equally or were better at recog-
nizing established CAN in contrast to CVT. This is not a sur-
prise, since both CVT and HRV are based on
electrocardiographic measurements and computed from
changes in R-R waves, so the HRV is affected by multiple
physiological factors with direct influence on heart rhythms
such as sleep, ingested meals, and physical activity. In con-trast, CVT performed better than the LF:HF ratio reflecting
sympato-vagal balance. This result is plausibly caused by
the fact that LF:HF ratio consists of two derived HRV indices
and thus, contains variability in both the nominator and
denominator, rather than CVT providing a better proxy of
sympato-vagal balance. Furthermore, crude comparison of
24-hour and 120-hour HRV time- and frequency-domain
indices within the CAN strata showed that all single HRV
indices were decreased in the established CAN groups com-
pared to no CAN, further supporting our results.
In the search for quick, clinically applicable autonomic
methods, a short recording of sudomotor function has sur-
faced as a potential tool [16]. However, recent controversy
has arisen regarding the biological plausibility of this mea-
sure [14]. Therefore, we explored the performance of ESC
compared to CVT to recognize established CAN and found
that ESC underperformed. ESC is believed to peripheral sym-
pathetic unmyelinated thin C-fibers, and is in the literature
associated with tests reflecting sympathetic function like
orthostatic hypotension and low-frequency power compo-
nents of HRV, rather than those reflecting parasympathetic
function such as the cardiovascular autonomic reflex test
used conducted by the Vagus device [26,27]. These parasym-
pathetic test are generally chosen as parasympathetic dener-
vation often is the first sign of cardiovascular autonomic
neuropathy. However, a study by Jacob et al. [28] did suggest
that hyperadrenergic orthostatic hypotension could an early
form of autonomic impairment, though this needs further
investigation.
Due to its asymptomatic nature, CAN is unfortunately
often well established and irreversible when recognized [29].
Therefore, early recognition should be the focus of clinical
progression as it will enable earlier prevention initiatives
and investigation of treatment possibilities [1,7,30]. A reason-
able approach might consist of reducing universal testing by
implementing a clinically applicable screening tool. As one
single abnormal result of three cardiovascular autonomic
reflex tests is considered sufficient for recognition of early
CAN, we investigated the performance of CVT as a screening
tool to recognize borderline CAN. By the use of a CVT cut-off
value of 5.2 LVS, our results indicated a good performance
with high sensitivity (88%), moderate specificity (63%), though
borderline significant. However, the moderate specificity is
caused by a single data point where one person had CVT val-
ues (12 LVS) considerably above the average of healthy partic-
ipants (9 LVS) [21]. Therefore, the suggested cut-off value for
screening purposes seems robust even though it did not reach
significance.
It is generally accepted that time-consuming HRV record-
ings (24-hours or more) are reproducible, stable over time,
and have increased sensitivity compared to short-term
recordings (5 to 30-minute) [23]. To our surprise, our results
indicated that a 5-minute recording of CVT performed slightly
better at recognizing borderline CAN than HRV indices derived
from 24-hour and 120-hour HRV indices. This finding chal-
lenges the general acceptance of the diagnostic applicability
of HRV indices in borderline CAN, which hitherto, has been
considered a sensitive test for early recognition of CAN in
asymptomatic patients [23]. The differences could be
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test as reference. Curiously, HF, the spectral HRV components
assumed to be most affected by efferent vagal activity and cir-
cadian activity, [23] was superior to CVT for recognizing bor-
derline CAN.
For recognition of early CAN in adults with type 1 diabetes,
Selvarajah et al. [16] have previously reported ESC to be lower
compared to those without CAN. Interestingly, Ang et al. [15]
showed that ESC values decreased in type 1 diabetes after
12 months, though this was not the case for other autonomic
tests including the Valsalva maneuver. Though our results
showed no crude difference in ESC between the CAN strata,
the AUC results indicated poor accuracy for recognizing bor-
derline CAN, with an AUC of 0.67 for the feet and 0.63 for the
hands; bothmeasures are inferior to CVT. This is the first time
that ECS has been compared with CVT, and our results are the
first to show that CVT performs better than sudomotor func-
tion for classifying CAN. Our results, however, are comparable
to those reported by Selvarajah et al., [16] although these
authors are the only ones to report better performance of
ESC in hands for recognizing CAN in comparison to ESC in
feet. Taken together, CVT could ease the testing practice for
health care professionals and decrease the number of unrec-
ognized cases.
This study is not without limitations. Firstly, this is a
cross-sectional pilot study of a relatively small cohort, and
thus, generalizing the results should be done with caution.
Secondly, the proportion of participants stratified to the pres-
ence of CAN may be underestimated due to selection bias, as
our exclusion criteria hamper the true prevalence by exclud-
ing potential participants with established cardiovascular dis-
ease from the study. Thirdly, in contrast to suggestions by the
Toronto consensus, [1] we did not measure orthostatic
hypotension as part of the CAN formula, primarily because
it is not part of the VagusTM procedures. Fourthly, the mean
CVT measure has been validated in the healthy, [31] and not
in those with diabetes; however, we standardized the record-
ing procedures in order to avoid potential fluctuations caused
by physiological and environmental factors. For example, the
circadian rhythm is known to influence CVT, CARTs, and ESC,
and therefore, all experimental procedures were recorded in
the mornings between 8.00 and 11:00. Additionally, though
CVT has been shown to decrease with age[21], we did not
use age-related normative values, which may impact or find-
ings. Fifthly, HRV was measured for 24-hours and 120-hours
and is therefore affected by multiple physiological factors
with direct influence on heart rhythms such as sleep,
ingested meals, and physical activity. However, weminimized
noise and artifacts by automatic filtering and processing in
order to avoid manual editing which could induce subjective
bias [32]. Finally, it would have benefited the study if we had
had measures of continuous glucose monitoring in order to
investigate differences in ‘‘time in range” in the three CAN
strata and we recommend that this be implemented in future
prospective longitudinal studies.
5.1. Conclusion
We suggest the implementation of a reliable, low cost, and
simple CVT measure with a clinically applicable cut-offvalue that may meet the unmet need for a suitable and
quick screening test for recognition of asymptomatic estab-
lished and borderline CAN. The 5-minute CVT measure per-
forms with acceptable sensitivity and specificity for
recognition of asymptomatic CAN. Although screening for
CAN is clinically recommended 5 years after diagnosis of
type 1 diabetes and yearly thereafter, this is rarely carried
out in the clinical setting due to resource-demanding proce-
dures. Ultimately, a quick screening test could decrease the
number of asymptomatic and undiagnosed CAN cases and
initiate earlier prevention initiatives, thereby effectively
improving glycaemic control, increased quality of life, and
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